A Head-to Head Comparison of Risankizumab and Ustekinumab as Second-Line Therapy in Moderate to Severely Active Crohn's Disease.

Gastroenterology

Lawson Health Research Institute, London, Ontario, Canada; Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.

Published: September 2024

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.gastro.2024.08.036DOI Listing

Publication Analysis

Top Keywords

head-to head
4
head comparison
4
comparison risankizumab
4
risankizumab ustekinumab
4
ustekinumab second-line
4
second-line therapy
4
therapy moderate
4
moderate severely
4
severely active
4
active crohn's
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!